Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models

Nina Maenhoudt(KU Leuven), Charlotte Defraye(KU Leuven), Matteo Boretto(KU Leuven), Žiga Jan(VIB-KU Leuven Center for Cancer Biology), Ruben Heremans(Universitair Ziekenhuis Leuven), Bram Boeckx(VIB-KU Leuven Center for Cancer Biology), Florian Hermans(Hasselt University), Ingrid Arijs(VIB-KU Leuven Center for Cancer Biology), Benoit Cox(KU Leuven), Els Van Nieuwenhuysen(Universitair Ziekenhuis Leuven), Ignace Vergote(Universitair Ziekenhuis Leuven), Anne‐Sophie Van Rompuy(KU Leuven), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), D. Timmerman(Universitair Ziekenhuis Leuven), Hugo Vankelecom(KU Leuven)
Stem Cell Reports
April 1, 2020
Cited by 187Open Access
Full Text

Abstract

Ovarian cancer (OC) represents the most dismal gynecological cancer. Pathobiology is poorly understood, mainly due to lack of appropriate study models. Organoids, defined as self-developing three-dimensional in vitro reconstructions of tissues, provide powerful tools to model human diseases. Here, we established organoid cultures from patient-derived OC, in particular from the most prevalent high-grade serous OC (HGSOC). Testing multiple culture medium components identified neuregulin-1 (NRG1) as key factor in maximizing OC organoid development and growth, although overall derivation efficiency remained moderate (36% for HGSOC patients, 44% for all patients together). Established organoid lines showed patient tumor-dependent morphology and disease characteristics, and recapitulated the parent tumor's marker expression and mutational landscape. Moreover, the organoids displayed tumor-specific sensitivity to clinical HGSOC chemotherapeutic drugs. Patient-derived OC organoids provide powerful tools for the study of the cancer's pathobiology (such as importance of the NRG1/ERBB pathway) as well as advanced preclinical tools for (personalized) drug screening and discovery.


Related Papers

No related papers found

Powered by citation graph analysis